



5 CHOSES À SAVOIR SUR LE VIRUS RESPIRATOIRE SYNCYTIAL

Le VRS est la cause la plus fréquente d'infection des voies respiratoires inférieures (telles que la bronchiolite et la pneumonie) chez les nourrissons et les jeunes enfants ^{1,2}



Le VRS est aussi la principale cause d'hospitalisation chez les nourrissons ^{3,4}

Le VRS est imprévisible.

Il est difficile de prédire quels nourrissons développeront une forme grave de la maladie nécessitant des soins médicaux ⁵⁻⁷



La plupart des hospitalisations dues au VRS surviennent chez des nourrissons nés à terme et en bonne santé ^{8,9}

+

+

+

Il n'existe actuellement aucun traitement ou option préventive disponible pour protéger tous les nourrissons contre le VRS ¹⁰⁻¹²



Tous les nourrissons ont besoin d'être protégés contre le VRS



REFERENCES :

1. R K. Respiratory Syncytial Virus Vaccines. Plotkin SA, Orenstein WA, Offitt PA, Edwards KM, eds Plotkin's Vaccines 7th ed Philadelphia. 2018;7th ed. Philadelphia:943-9.
2. Shi T, McAllister DA, O'Brien KL, et al; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958
3. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. Journal of perinatology : official journal of the California Perinatal Association. 2016;36(11):990-6
4. Leader S., et al. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatrics 2003; vol 143:S127-S132.
5. Arriola CS et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2019;DOI: 10.1093/jpids/piz087 J Pediatric Infect Dis Soc. 2019. DOI: 10.1093/jpids/piz087
6. Hall CB, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341-e348
7. Bianchini, S.; Silvestri, E.; Argentiero, A.; Fainardi, V.; Pisi, G.; Esposito, S. Role of Respiratory Syncytial Virus in Pediatric Pneumonia. Microorganisms 2020, 8, 2048. <https://doi.org/10.3390/microorganisms8122048>.
8. Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. Journal of the Pediatric Infectious Diseases Society. 2020;9(5):587-95.
9. Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146(1).
10. Villafana T, et al. Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines. 2017;16:1-39.
11. World Health Organization. Preferred product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines. 2017. Accessed June 2021.
12. Centers for Disease Control and Prevention. Respiratory Syncytial Virus (RSV): Symptoms and Care. <https://www.cdc.gov/rsv/about/symptoms.html>. Accessed June 2021.